Global HIV Vaccine Enterprise
What the Global HIV Vaccine Enterprise does
The Global HIV Vaccine Enterprise promotes HIV vaccine development by sharing knowledge, fostering collaboration, prioritizing HIV vaccine R&D on the global health agenda, and supporting early-career African researchers and advocates through capacity-building initiatives. It was established in 2003 and became a programme of the IAS in 2018.
The Global HIV Vaccine Enterprise in context
Although there are multiple HIV prevention options, access and uptake are uneven, which means that HIV incidence remains worryingly high in some areas and populations. An HIV vaccine holds the key to halting the pandemic by decreasing transmission and new acquisitions of HIV.
I’m very excited now that I’m in the room with such great minds, especially for someone from Lesotho. After the HIV Vaccine Advocacy Academy, now they will hear from me!
2023 HIV Vaccine Advocacy Academy participant
The Global HIV Vaccine Enterprise in action
The Global HIV Vaccine Enterprise shares knowledge, fosters collaboration, enables solutions and expands support critical to the development of – and future access to – an HIV vaccine.
The IAS Global HIV Vaccine Enterprise:
-
Strengthens the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio
-
Expands and diversifies engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field
-
Mobilizes knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research
Key numbers
Upcoming activities
-
HIV Vaccine Advocacy Academy – December 2024
-
EU Vaccine Reference Group meeting – early 2025
Contact
In partnership with
